Blood Lead Levels and Death from All Causes, Cardiovascular Disease, and Cancer: Results from the NHANES III Mortality Study by Schober, Susan E. et al.
1538 VOLUME 114 | NUMBER 10 | October 2006 • Environmental Health Perspectives
Research
Toxic effects of exposure to high levels of lead
among adults in occupational settings and
from poisonings include neurologic and renal
impairment as well as effects on other organ
systems [Agency for Toxic Substances and
Disease Registry (ATSDR) 1999]. Environ-
mental exposure to lead—exposure much
lower than that found in occupational set-
tings—is associated with long-term adverse
effects, particularly on blood pressure (Cheng
et al. 2001; Glenn et al. 2003; Hertz-Picciotto
and Croft 1992; Hu et al. 1996; Moller and
Kristensen 1992; Nash et al. 2003), renal
function (Kim et al. 1996; Muntner et al.
2003; Payton et al. 1994; Staessen et al. 1992;
Tsaih et al. 2004), and cognition (Payton
et al. 1998; Weisskopf et al. 2004; Wright
et al. 2003). Recent reports suggest that even
blood lead levels that are currently typical in
the U.S. population are associated with renal
dysfunction (Muntner et al. 2005) and
peripheral arterial disease (Muntner et al.
2005; Navas-Acien et al. 2004). Lead and lead
compounds are reasonably anticipated to be
human carcinogens based on evidence from
occupational mortality and animal studies
[National Toxicology Program (NTP) 2005].
Lead exposure declined dramatically
beginning in the late 1970s largely because of
mandated removal of lead from gasoline, from
paint, and to a lesser extent, from solder used
in cans (Annest et al. 1983; Pirkle et al. 1994).
Blood lead measurements from the National
Health and Nutrition Examination Surveys
(NHANES) have provided documentation of
lead exposure in the U.S. population beginning
with data from NHANES II conducted during
1976–1980. Among person 1–74 years of age,
the geometric mean of blood lead level dropped
from 12.8 µg/dL in 1976–1980 to 2.8 µg/dL
in 1988–1991 (Annest et al. 1983), and to
2.3 µg/dL in 1991–1994 [Centers for Disease
Control and Prevention (CDC) 1997]. 
Analyses of mortality follow-up data for
participants of NHANES II suggested an
increased risk of mortality at blood lead levels
> 20 µg/dL (Jemal et al. 2002; Lustberg and
Silbergeld 2002). Mortality follow-up through
the year 2000 is now available for NHANES
III participants. The purpose of our study was
to examine the risk of mortality from all
causes, cardiovascular disease, and cancer in
relation to blood lead levels observed for adult
participants of NHANES III. 
Methods
NHANES III was ﬁelded in two phases, the
first from 1988 through October 1991 and
the second from November 1991 through
1994. The survey consisted of a household
interview and a standardized physical exami-
nation in a mobile examination center. The
NHANES III sample was selected through a
complex, multistage probability design. The
survey has been described in detail elsewhere
(CDC 1994). 
During the physical examination, blood
was obtained by venipuncture for all survey
participants ≥ 1 year of age. Blood lead con-
centrations were measured by graphite furnace
atomic absorption spectrophotometry and
expressed in micrograms per deciliter. Details
regarding laboratory methods and quality con-
trol procedures have been described previously
(Pirkle et al. 1994). 
NHANES III participants ≥ 17 years of
age were eligible for passive mortality follow-
up, which has been completed for deaths
occurring through December 2000. Mortality
information is based on the results of a proba-
bilistic match between NHANES III and the
National Death Index records [National
Center for Health Statistics (NCHS) 2006].
This analysis was limited to persons
≥ 40 years of age at the time of the examina-
tion. Of the 10,202 persons ≥ 40 years of age,
9,762 (95.7%) had a blood lead measure-
ment at baseline. Five persons were excluded
because of insufficient information to allow
for follow-up, resulting in a sample of
9,757 persons. The median length of follow-
up was 8.55 years, during which there were
2,515 deaths (25.8% of participants). The
International Classification of Diseases, Tenth
Revision (ICD-10; NCHS 2006) was used to
identify deaths due to malignant neoplasm
(ICD-10 codes C00–C97) and major cardio-
vascular disease (ICD-10 codes I00–I78).
Persons who were not matched to a death
record were considered alive through the
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BACKGROUND: Analyses of mortality data for participants examined in 1976–1980 in the second
National Health and Nutrition Examination Survey (NHANES II) suggested an increased risk of
mortality at blood lead levels > 20 µg/dL. Blood lead levels have decreased markedly since the late
1970s. In NHANES III, conducted during 1988–1994, few adults had levels > 20 µg/dL. 
OBJECTIVE: Our objective in this study was to determine the risk of mortality in relation to lower
blood lead levels observed for adult participants of NHANES III.
METHODS: We analyzed mortality information for 9,757 participants who had a blood lead measure-
ment and who were ≥ 40 years of age at the baseline examination. Using blood lead levels catego-
rized as < 5, 5 to < 10, and ≥ 10 µg/dL, we determined the relative risk of mortality from all causes,
cancer, and cardiovascular disease through Cox proportional hazard regression analysis.
RESULTS: Using blood lead levels < 5 µg/dL as the referent, we determined that the relative risk of
mortality from all causes was 1.24 [95% conﬁdence interval (CI), 1.05–1.48] for those with blood
levels of 5–9 µg/dL and 1.59 (95% CI, 1.28–1.98) for those with blood levels ≥ 10 µg/dL (p for
trend < 0.001). The magnitude of risk was similar for deaths due to cardiovascular disease and
cancer, and tests for trend were statistically signiﬁcant (p < 0.01) for both causes of death.
CONCLUSION: In a nationally representative sample of the U.S. population, blood lead levels as low
as 5–9 µg/dL were associated with an increased risk of death from all causes, cardiovascular disease,
and cancer.
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sored 31 December 2000. 
Blood lead levels were categorized as < 5,
5 to < 10, and ≥ 10 µg/dL. The sample size
for persons with blood lead levels ≥ 20 µg/dL
was too small to provide reliable estimates of
mortality risk for this group. Because of the
skewed distribution of blood lead concentra-
tions, log-transformed values were used for
additional analyses using lead levels as a con-
tinuous variable. 
A participant’s age was defined as his or
her age in years at the baseline examination.
Race/ethnicity was categorized as non-
Hispanic white, non-Hispanic black, Mexican
American, and other. Education level was cat-
egorized as < 12 years or ≥ 12 years of educa-
tion. Total family income was defined as
< $20,000/year or ≥ $20,000/year. Region, as
defined by the U.S. Census Bureau (2006),
was recorded as Northeast, Midwest, West, or
South. Urban status of residence was deﬁned
by population size and place of residence, and
categorized into two groups: central or fringe
counties of metropolitan areas with popula-
tion size of ≥ 1 million versus all other areas.
History of cigarette smoking was categorized
as never, former, or current. Alcohol con-
sumption was used as a continuous variable
and defined by summing the number of
drinks of beer, wine, or liquor consumed per
week. More than 21 drinks was truncated and
counted as 21. 
We used Cox proportional hazard regres-
sion analysis, using age as the time scale to
examine the relative hazard (or relative risk) of
mortality from all causes, cancer, and cardio-
vascular disease using categories of blood lead
concentrations as described above (Korn et al.
1997). As recommended by Korn et al.
(1997), we stratified the baseline hazard by
birth cohort; we used 6-year intervals. This
controls for potential cohort differences in
cumulative exposure to lead before the late
1970s, when current exposure to lead began to
decline dramatically (Annest et al. 1983;
Pirkle et al. 1994). Blood lead levels largely
reflect current exposure (Rabinowitz et al.
1976) and are an imperfect measure of a per-
son’s lifetime exposure to lead. Because cur-
rent lead exposure and blood lead levels
continued to decline over the 6-year period of
blood collection in NHANES (CDC 1997;
Pirkle et al. 1994), we also stratiﬁed the base-
line hazard by survey phase. For cause-speciﬁc
analyses, follow-up for those who died from
other causes was censored at the age of death. 
Initial models assessed univariate associa-
tions of covariates and mortality. Next, we
constructed multivariate proportional hazard
models to examine the association of lead
exposure and mortality after adjusting for
potential confounders. All two-way inter-
actions with blood lead category were assessed.
We assessed the proportional hazard assump-
tion by examining the consistency of the rela-
tive hazards of mortality across three age
groups. We defined three age categories,
40–74, 75–84, and ≥ 85 years, so that there
were an approximately equal number of deaths
from all causes in each category. Study subjects
can be included in more than one age group as
their ages change during the follow-up period.
Because the cancer mortality and blood lead
relationship was different for men and women
in a previous study of the NHANES II cohort,
we also stratiﬁed multivariate models separately
for males and females. 
We analyzed the dose–response relation-
ship of blood lead and mortality in two ways.
First, the multivariate-adjusted relative risks
across the three blood lead categories were
tested for trend. A linear term consisting of
the median values for each lead group was
placed in the proportional hazards model
instead of the dummy variables for each
group, and this linear term was analyzed
using a Wald test. Second, the dose–response
relationship between lead and mortality from
all causes was evaluated using log-transformed
blood lead concentration as a continuous vari-
able with a ﬁve-knot cubic regression spline in
the multivariate proportional hazards model
(Durrleman and Simon 1989). We used a
Wald test to evaluate the dose–response
relationship. 
Statistical analyses were conducted using
the SAS System for Windows (release 9.1;
SAS Institute Inc., Cary, NC) and SUDAAN
(release 9.0; Research Triangle Institute,
Research Triangle Park, NC). All analyses
included sample weights that accounted for
the unequal probabilities of selection and
nonresponse. All variance calculations incor-
porated the sample weights and accounted for
the complex sample design using Taylor series
linearization. All significance tests were two-
sided using p < 0.05 as the level of statistical
signiﬁcance.
Results
Table 1 summarizes characteristics of the
NHANES III cohort by blood lead categories.
Person-years of follow up were approximately
53,000, 20,000, and 4,500 by blood lead cate-
gories < 5, 5–9, and ≥ 10 µg/dL, respectively.
Remaining estimates are weighted by the sam-
ple weights. Blood lead levels increased with
age. Blood lead concentrations were dispro-
portionately higher for men, non-Hispanic
blacks, those with low income, those with
educational attainment of < 12 years, current
smokers, and residents of the Northeast, and
persons who participated in the ﬁrst phase of
the survey. Alcohol intake was positively asso-
ciated with blood lead concentrations. No dif-
ferences in blood lead concentrations by urban
status of residences were noted.
The number of deaths and multivariate-
adjusted relative risks of mortality due to all
causes, cardiovascular disease, and cancer by
blood lead category are presented in Table 2.
The multivariate results exclude 71 persons
with missing information on education level,
for a final sample size of 9,686. After this
exclusion, there were a total of 2,485 deaths
from all causes, 1,189 from cardiovascular
disease, and 543 from cancer. For each cate-
gory of deaths, statistical testing did not sup-
port the null hypothesis that proportional
Blood lead levels and mortality risk, NHANES III
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Table 1. Characteristics of the study cohort by blood lead level.
Blood lead level (µg/dL)
Characteristic < 5 5–9 > 10
Sample size 6,608 2,532 617
Person-years 53,398 19,939 4,509
Median blood lead level (µg/dL) 2.6 6.3 11.8
Mean age at baseline (years) 57.0 60.6 62.0
Male (%) 39.1 65.2 74.2
Race/ethnicity (%)
Non-Hispanic white 82.7 78.1 65.7
Non-Hispanic black 7.4 12.3 22.6
Mexican-American 3.4 3.5 4.3
Other 6.5 6.1 7.5
Total family income < $20,000 (%) 29.8 41.2 52.3
Education level < 12 years (%) 26.2 39.0 50.8
Smoking status at baseline (%)
Never 48.1 26.1 19.3
Former 33.8 39.0 36.5
Current 18.1 34.9 44.2
Mean alcohol intake (drinks/week) 2.0 4.6 5.5
Census region (%)
Northeast 17.4 29.1 36.2
Midwest 25.1 25.2 17.8
South 36.3 27.8 31.7
West 21.2 18.0 14.3
Urban status (%) 45.6 52.1 51.3
Phase 1 of survey (%) 44.4 58.2 65.3hazards were constant by age, although the
lead-mortality relationships were generally
consistent across age strata. For completeness,
age-stratiﬁed results are shown in addition to
results for all ages combined. The following
covariates were included in all multivariate
models: sex, race/ethnicity, education level,
and smoking status. Census region and urban
status of residence were not predictive, and
alcohol intake was weakly predictive of mor-
tality in our analysis. Including these three
covariates in the analysis did not alter the
blood lead and mortality relationships; there-
fore, we excluded these three covariates from
the ﬁnal multivariate models. Socioeconomic
status, as indicated by either annual family
income (categorized as < $20,000 and
≥ $20,000) or education level was an impor-
tant confounder in the multivariate analyses.
We chose to use education level rather than
income in our ﬁnal models because there was
less missing information for this variable. In
general, interaction terms between lead and
covariates were not statistically signiﬁcant. We
found a p-value of 0.02 for the interaction
terms lead × education in the cardiovascular
disease model and lead × race/ethnicity in the
cancer mortality model; however, the inter-
active effects were not large and did not alter
the direction of the lead–mortality relation-
ships. Therefore, we did not include these
terms in our ﬁnal models.
In general, we found an increased risk of
mortality from all causes with increasing blood
lead levels (Table 2), where the reference cate-
gory was blood lead levels < 5 µg/dL. For all
ages combined, the relative risks of mortality
were 1.24 [95% confidence interval (CI),
1.05–1.48) for those with blood levels of
5–9 µg/dL and 1.59 (95% CI, 1.28–1.98) for
those with blood levels of ≥ 10 µg/dL (test for
trend, p < 0.001). For mortality due to cardio-
vascular disease, there was also a pattern of
increasing risk with increasing blood lead. For
all ages combined, the estimated relative risk of
mortality from cardiovascular disease was 1.20
(95% CI, 0.93–1.55) for those with blood lead
levels of 5–9 µg/dL and 1.55 (95% CI,
1.16–2.07) for those with blood lead levels of
≥ 10 µg/dL (test for trend, p < 0.01). For all
ages combined, the estimated relative risk of
mortality from cancer was 1.44 (95% CI,
1.12–1.86) for those with blood lead levels of
5–9 µg/dL and 1.69 (95% CI, 1.14–2.52) for
those with blood lead levels of ≥ 10 µg/dL (test
for trend, p < 0.01). 
We further explored the dose–response
relationship between blood lead concentrations
and mortality from all causes by modeling the
proportional hazards using log-transformed
blood lead levels on a continuous scale with a
five-knot cubic regression spline. The spline
analysis results displayed as relative hazards
using a referent blood lead level of 1.5 µg/dL
(12.5th percentile) and 95% CIs are shown
graphically in Figure 1. This result is adjusted
for all covariates included in the final model
shown in Table 2. The lower bound of the
95% CI of the relative hazard exceeds unity at
a blood lead concentration of approximately
5.5 µg/dL. The relative hazard remains < 2 for
blood lead levels ≤ 10 µg/dL.
Discussion
In this analysis of mortality among a large
cohort of adults representative of the U.S.
population, we found an increased risk of
death from all causes, cardiovascular disease,
and cancer associated with elevated blood lead
levels. Overall, the increase in risk was small;
however, the increase was observed for blood
lead levels as low as 5–9 µg/dL. Our ﬁnding
of dose–response relationships between mor-
tality risk and increasing blood lead levels for
all three classes of death strengthens the con-
clusion that blood lead levels are associated
with an increased risk of mortality. 
Previous research has examined mortality
risk and blood lead levels in the general popu-
lation of the United States using mortality
follow-up data for participants 30–74 years
of age from NHANES II, a study with base-
line data collected during 1976–1980 and
follow-up through 1992 (Jemal et al. 2002;
Lustberg and Silbergeld 2002). Lustberg and
Silbergeld (2002) analyzed data for persons of
all races and concluded that risk of mortality
from all causes, circulatory disease, and cancer
was elevated for persons with blood lead levels
of 20–29 µg/dL compared with those with
levels < 10 µg/dL. Multivariate-adjusted
results did not show an increased risk for those
with blood lead levels of 10–19 µg/dL. In an
analysis limited to white participants, Jemal
et al. (2002) found no dose–response relation-
ship between quartiles of blood lead and risk
of death from cancer, but they did find evi-
dence of a threshold effect for women, with
risk becoming signiﬁcantly elevated at a blood
lead concentration of approximately 24 µg/dL. 
The results of our study showing increased
mortality at levels as low as 5–9 µg/dL are con-
sistent with other research that suggests health
effects associated with low levels of lead expo-
sure. Recent cross-sectional analyses of the cur-
rent, ongoing NHANES, with data from
1999–2002, suggest an increased risk of periph-
eral arterial disease, hypertension, and renal dys-
function in a population with blood lead levels
of approximately 2 µg/dL on average (Muntner
et al. 2005; Navas-Acien et al. 2004). Other
analyses of population-based studies support
these results. For example, in the Normative
Aging Study, blood lead levels < 10 µg/dL were
associated with renal function and cognitive
impairment (Kim et al. 1996; Payton et al.
1994, 1998; Weisskopf et al. 2004; Wright
et al. 2003). Cross-sectional analyses of the
NHANES III cohort have shown that blood
lead levels are related to increased blood pres-
sure (Nash et al. 2003) and decreased renal
function (Muntner et al. 2003). 
Exposure misclassiﬁcation is a potentially
important limitation of our analysis. We clas-
sified exposure based on blood lead levels
Schober et al.
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Table 2. Multivariate adjusteda relative risks for all-cause, cancer, and cardiovascular disease mortality
by blood lead level and age category. 
Cause of death/ No. of  Relative risk (95% CI) by age category (years)
blood lead level deaths 40–74 75–84 > 85  All
All causes
< 5 µg/dL 1,402 1 1 1 1
5–9 µg/dL 828 1.30 (1.03–1.65) 1.38 (1.04–1.83) 0.98 (0.85–1.14) 1.24 (1.05–1.48)
≥ 10 µg/dL 255 1.73 (1.28–2.35)b 1.39 (0.93–2.08)c 1.67 (1.11–2.53) 1.59 (1.28–1.98)b
Cardiovascular disease
< 5 µg/dL 684 1 1 1 1
5–9 µg/dL 394 1.11 (0.79–1.56) 1.41 (0.87–2.28) 1.07 (0.87–1.31) 1.20 (0.93–1.55)
≥ 10 µg/dL 111 1.47 (0.93–2.33) 1.71 (0.94–3.09)c 1.45 (0.85–2.48) 1.55 (1.16–2.07)d
Cancer
< 5 µg/dL 282 1 1 1 1
5–9 µg/dL 194 1.44 (0.91–2.28) 1.46 (1.03–2.07) 1.44 (0.92–2.26) 1.44 (1.12–1.86)
≥ 10 µg/dL 67 2.27 (1.38–3.74)d 0.80 (0.38–1.69) 2.2 (1.13–4.29)d 1.69 (1.14–2.52)d
CI, conﬁdence interval.
aAdjusted for sex, race/ethnicity, education, and smoking status. bp-Value for trend test < 0.001. cp-Value for trend test
< 0.05. dp-Value for trend test < 0.01.
Figure 1. Relative risk of all cause mortality for dif-
ferent blood lead levels compared with referent
level of 1.5 µg/dL (12.5th percentile). The solid line
shows the fitted five-knot spline relationship; the
dashed lines are the point-wise upper and lower
95% CIs.
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0.0measured at only one point in time. Most
(75–95%) lead in the body is found in bone
(Saltzman et al. 1990), where the half-life is
5–19 years (Rabinowitz 1991). Therefore,
measures of bone lead indicate cumulative,
long-term exposure and are the best measure to
study chronic effects. The half-life of lead in
blood is approximately 1 month (Rabinowitz
et al. 1976); thus blood levels are related to
current exposure. Lead is released from bone
through resorption, such as occurs with aging,
and this contributes to levels found in blood
(Hu et al. 1998; Smith et al. 1996). Older per-
sons in the NHANES III cohort were more
likely to have higher cumulative lead exposure,
and their blood lead levels may be dispropor-
tionately influenced by release of lead from
bone stores compared with younger persons. 
That our results show an increased risk of
mortality at lower blood lead levels than the
mortality studies of the NHANES II cohort
may be related to exposure classiﬁcation being
based on a single blood lead measurement.
Blood lead levels of NHANES III participants
were close to 80% lower than in the NHANES
II cohort, and few adults had blood lead levels
> 20 µg/dL (CDC 1997; Pirkle et al. 1994).
This reﬂects reductions in the current exposure
of the study participants because of the elimi-
nation of lead from gasoline and other envi-
ronmental sources. We speculate that the
difference in cumulative lead exposure among
adults across the two surveys is relatively
smaller than the difference in current exposure.
For example, it is likely that within the same
birth cohort, most persons who had blood lead
levels > 20 µg/dL in 1976–1980 would have
levels < 10 µg/dL in 1988–1994. The particu-
larly dramatic decrease in blood levels that
occurred during the NHANES II (Annest
et al. 1983) makes the evaluation of a dose–
response relationship of blood lead level and
mortality even more problematic and may
explain why the previous analyses of NHANES
II (Jemal et al. 2002; Lustberg and Silbergeld
2002) did not ﬁnd as strong a dose effect as in
our present analyses of NHANES III, which
had more stable blood lead levels. 
It is not possible to differentiate an acute
effect of lead in blood from a chronic effect in
studies that only use blood lead levels to indi-
cate exposure (Hu et al. 1998). With advances
in measuring bone lead through X-ray ﬂuores-
cence, several studies have evaluated the associ-
ation of health effects with both bone and
blood lead measures. Both cross-sectional and
longitudinal analyses of the Normative Aging
Study suggest that cumulative exposure, as well
as current exposure, to lead is associated with
declines in renal function (Kim et al. 1996;
Payton et al. 1994) and cognition (Payton
et al. 1998; Weisskopf et al. 2004; Wright
et al. 2003). Results from the Normative Aging
Study suggest that cumulative but not current
exposure is associated with an increased risk of
hypertension (Tsaih et al. 2004); however, in a
longitudinal study of a cohort who had previ-
ous occupational exposure, Glenn et al. (2003)
concluded that the effect of lead on blood pres-
sure is consistent with both acute and chronic
modes of action.
From the present study we conclude that
mortality is associated with lead exposure as
indicated by a single blood lead measurement
typical for the U.S. adult population during
1988–1994. Extrapolating from this to mor-
tality risk related to cumulative lead exposure
or blood lead measurements from different
calendar periods can only be speculative. The
blood lead and mortality relationship that we
observed may be due to lead being a surrogate
for some other factor that is associated with
an increase in mortality. For example, socio-
economic status may not be sufﬁciently con-
trolled for by measures of education level or
family income. However, we adjusted for
well-know confounders without observing a
substantial reduction in the blood lead
relationship. Also, the observed relationships
for each category of mortality were fairly con-
sistent across age and groups. 
The major strengths of our study, that the
NHANES cohort is representative of the U.S.
population and that the sample size is large
enough to evaluate small differences in risk,
are notable. Our analysis adds to the body of
evidence demonstrating adverse health conse-
quences related to blood lead levels that fall
below current levels of concern. Further
research is needed to assess cumulative expo-
sure and adverse health consequences, includ-
ing mortality, for persons who were not
exposed to high levels of lead in the environ-
ment that were typical before lead was
removed from gasoline in the late 1970s.
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